Rates of neisseria meningitidis: Increasing in young

Pediatric Annals

Volumn 33, Issue 9, 2004, Pages 590-595

  Gaur, Sunanda ^a   Malhotra, Amisha ^b   Whitley Williams, Patricia ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Pediatrics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

APPETITE DISORDER; CHILD; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEVER; HEADACHE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFANT; IRRITABILITY; MALAISE; MENINGOCOCCOSIS; MORBIDITY; MYALGIA; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; SIDE EFFECT; UNITED STATES;

EID: 4544324133     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20040901-10     Document Type: Review

References (33)

1. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-7):1-10.
2. Offit PA, Peter G. The meningococcal vaccine - public policy and individual choices. N Engl J Med. 2003;349(24):2353-2356.
3. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-7):13-20.
4. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180(6):1894-1901.
5. Greenwood B. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93(4):341-353.
6. Novelli VM, Lewis RG, Dawood ST. Epidemic group A meningococcal disease in Haj pilgrims. Lancet. 1987;2(8563):863.
7. Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet. 2000;356(9248):2159.
8. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307-1326.
9. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388.
10. Woods CR, Rosenstein N, Perkins BA. Neisseria meningitis outbreaks in the United States, 1994-97. Presented at: 38th Annual Meeting of the Infectious Disease Society of America. November 12-15, 1998; Denver, CO.
11. Apicella MA. Neisseria meningitides. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Vol 2. Philadelphia, PA: Churchill Livingstone; 2000:2228-2241.
12. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138(12):4402-4407.
13. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am. 2001;15(1):155-169.
14. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec. 2002;77(40):331-339.
15. Wildes SS, Tunkel AR. Meningococcal vaccines: a progress report. BioDrugs. 2002;16(5):321-329.
16. Dull P, Rosenstein N. Meningococcal disease and vaccines. Pediatr Ann. 2001;30(6):358-361.
17. Soriano-Gabarro M, Stuart JM, Rosenstein NE. Vaccines for the prevention of meningococcal disease in children. Semin Pediatr Infect Dis. 2002;13(3):182-189.
18. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-5):13-21.
19. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics. 2000;106(6):1500-1504.
20. Keyserling HL, Papa T, Bybel M. A comparative trial of the safety and immunogenicity of an experimental tetravalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine versus a licensed meningococcal (A, C, Y, and W-135) polysaccharide vaccine in health adolescents. Presented at: 43rd Interscience Conference on Antimicrobal Agents and Chemotherapy. September 14-17. 2003; Chicago, IL.
21. Pichichero ME, Casey JR, Papa T, et al. A comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal diptheria conjugate vaccine (MCV-4) versus quadrivalent polysaccharide vaccine (menomune, ps) in children 2-10 years of age. Presented at: 43rd Interscience Conference on Antimicrobal Agents and Chemotherapy. September 14-17. 2003; Chicago, IL.
22. Wachter K. New conjugate meningococcal vaccine on scene. Ped News. 2004;38(3):11.
23. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 2001;20(2):153-159.
24. Choo S, Zuckerman J, Goilav C, et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine. 2000;18(24):2686-2692.
25. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183(1):160-163.
26. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58-S67.
27. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51(9):717-722.
28. Ruggeberg J, Heath PT. Safety and efficacy of meningococcal group C conjugate vaccines. Expert Opin Drug Saf. 2003;2(1):7-19.
29. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365-366.
30. MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis. 2001;183(1):97-104.
31. MacLennan J, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283(21):2795-2801.
32. Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19(20-22):2924-2931.
33. Maiden MC, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829-1831.